{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-090056","form_type":"8-K","ticker":"TELA","cik":"0001561921","company_name":"TELA Bio, Inc.","filed_at":"2026-08-04T11:08:37+00:00","discovered_at":"2026-08-04T11:10:03.447898+00:00","generated_at":"2026-08-04T11:10:11.656837+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TELA Bio CEO Antony Koblish departs; Heather Getz appointed CEO and director","bullets":["Antony Koblish ceased as CEO and resigned from board on Aug 3, 2026; no disagreement with company.","Heather Getz appointed CEO and Class II director effective Aug 3, 2026; 25+ years healthcare experience.","Employment agreement: $650k base salary, 100% target bonus, severance, and initial equity grants.","Initial equity grants: 1,365,000 standard options, 1,005,000 premium-priced options, 500,000 RSUs.","Potential top-up grants if equity financings within 18 months; total could reach 5% of outstanding shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-090056","json":"https://secwatch.observer/filing/0001104659-26-090056.json","markdown":"https://secwatch.observer/filing/0001104659-26-090056.md","text":"https://secwatch.observer/filing/0001104659-26-090056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926090056/0001104659-26-090056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1561921/000110465926090056/tm2622121d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T11:10:11.656837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}